There is a much higher risk of brain blood clots from Covid-19 infection than there is from vaccines against the disease, British researchers said on April 15, after the rollout of inoculations was disrupted by reports of rare clots.
Six months after a Covid-19 diagnosis, more than 33 percent of people exhibited some form of brain damage, according to a study appearing in Lancet Psychiatry.
Oxford, U.K.-based Vaccitech reportedly filed confidentially in the United States for an initial public offering (IPO) on the Nasdaq.
The United States may not need AstraZeneca’s Covid-19 vaccine, even if it wins U.S. regulatory approval, Anthony Fauci, the nation’s top infectious disease doctor told Reuters on April 1.
According to a research collaboration among UCLA investigators and Merck KGaA, berzosertib has shown promise for Covid-19 and is also being touted for the drug’s unusually broad effect in treating a range of cancers.
To challenge the status quo reporting of mass-shootings, the Columbia Journalism Review (CJR) is bringing together some of the biggest names in journalism to help chart a new path forward for covering mass shootings.
AstraZeneca released primary analysis showing that the company’s AZD1222 vaccine demonstrated 76 percent efficacy against symptomatic Covid-19, 100 percent efficacy against severe or critical disease and hospitalizations, and 85 percent efficacy against symptomatic Covid-19 in people 65 years and older.
Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s Covid-19 vaccine, raised $168 million in a Series B financing round that will be used to support development of its own lead candidates in oncology and infectious disease.
A World Health Organization (WHO) vaccine safety panel said on March 17 that it considers that the benefits of the AstraZeneca Covid-19 vaccine outweigh its risks and recommends that vaccinations continue.
Preliminary data from a study conducted at the University of Oxford indicates that the Covid-19 vaccine developed by AstraZeneca is effective against the Brazilian variant P1, a source with knowledge of the study told Reuters on March 5.